Bacteriophage Application for Difficult-To-Treat Musculoskeletal Infections: Development of a Standardized Multidisciplinary Treatment Protocol

Bacteriophage therapy has recently attracted increased interest, particularly in difficult-to-treat infections. Although it is not a novel concept, standardized treatment guidelines are currently lacking. We present the first steps towards the establishment of a “multidisciplinary phage task force” (MPTF) and a standardized treatment pathway, based on our experience of four patients with severe musculoskeletal infections. After review of their medical history and current clinical status, a multidisciplinary team found four patients with musculoskeletal infections eligible for bacteriophage therapy within the scope of Article 37 of the Declaration of Helsinki. Treatment protocols were set up in collaboration with phage scientists and specialists. Based on the isolated pathogens, phage cocktails were selected and applied intraoperatively. A draining system allowed postoperative administration for a maximum of 10 days, 3 times per day. All patients received concomitant antibiotics and their clinical status was followed daily during phage therapy. No severe side-effects related to the phage application protocol were noted. After a single course of phage therapy with concomitant antibiotics, no recurrence of infection with the causative strains occurred, with follow-up periods ranging from 8 to 16 months. This study presents the successful outcome of bacteriophage therapy using a standardized treatment pathway for patients with severe musculoskeletal infection. A multidisciplinary team approach in the form of an MPTF is paramount in this process.

[1]  R. Schooley,et al.  Successful treatment of antibiotic resistant poly-microbial bone infection with bacteriophages and antibiotics combination. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Y. Tanji,et al.  Peculiarities of Staphylococcus aureus phages and their possible application in phage therapy , 2019, Applied Microbiology and Biotechnology.

[3]  J. Pirnay,et al.  Processing Phage Therapy Requests in a Brussels Military Hospital: Lessons Identified , 2019, Viruses.

[4]  A. Rousseau,et al.  Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. , 2019, The Lancet. Infectious diseases.

[5]  O. Patey,et al.  Clinical Indications and Compassionate Use of Phage Therapy: Personal Experience and Literature Review with a Focus on Osteoarticular Infections , 2018, Viruses.

[6]  K. Moelling,et al.  A Wake-Up Call: We Need Phage Therapy Now , 2018, Viruses.

[7]  R. Chemaly,et al.  A Systematic and Critical Review of Bacteriophage Therapy Against Multidrug-resistant ESKAPE Organisms in Humans. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  Mikhail A. Dziadzko,et al.  Salvage Debridement, Antibiotics and Implant Retention (“DAIR”) With Local Injection of a Selected Cocktail of Bacteriophages: Is It an Option for an Elderly Patient With Relapsing Staphylococcus aureus Prosthetic-Joint Infection? , 2018, Open forum infectious diseases.

[9]  M. Payne,et al.  Bacteriophage Therapy: Clinical Trials and Regulatory Hurdles , 2018, Front. Cell. Infect. Microbiol..

[10]  Benoît Blaysat,et al.  Towards standardized mechanical characterization of microbial biofilms: analysis and critical review , 2018, npj Biofilms and Microbiomes.

[11]  Mikhail A. Dziadzko,et al.  Innovations for the treatment of a complex bone and joint infection due to XDR Pseudomonas aeruginosa including local application of a selected cocktail of bacteriophages , 2018, The Journal of antimicrobial chemotherapy.

[12]  I. Huys,et al.  The Magistral Phage , 2018, Viruses.

[13]  M. Nielsen,et al.  Metagenomic Analysis of Therapeutic PYO Phage Cocktails from 1997 to 2014 , 2017, Viruses.

[14]  H. Abdelbary,et al.  Current review—The rise of bacteriophage as a unique therapeutic platform in treating peri‐prosthetic joint infections , 2017, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[15]  Henry C. Lin,et al.  Phage therapy: An alternative to antibiotics in the age of multi-drug resistance , 2017, World journal of gastrointestinal pharmacology and therapeutics.

[16]  A. Trampuz,et al.  „Beyond antibiotic therapy“ – Zukünftige antiinfektiöse Strategien – Update 2017 , 2017, Der Unfallchirurg.

[17]  L. Debarbieux,et al.  The Lysis of Pathogenic Escherichia coli by Bacteriophages Releases Less Endotoxin Than by β-Lactams , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  K. Gregorczyk,et al.  Phage Therapy in Bacterial Infections Treatment: One Hundred Years After the Discovery of Bacteriophages , 2016, Current Microbiology.

[19]  R. G. Richards,et al.  Infection after fracture fixation: Current surgical and microbiological concepts. , 2016, Injury.

[20]  S. Sillankorva,et al.  Bacteriophage-encoded depolymerases: their diversity and biotechnological applications , 2016, Applied Microbiology and Biotechnology.

[21]  S. Adhya,et al.  Phage Therapy: Current Research and Applications , 2015 .

[22]  E. Mylonakis,et al.  Antibacterial bioagents based on principles of bacteriophage biology: an overview. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  Yan Zhang,et al.  PATRIC, the bacterial bioinformatics database and analysis resource , 2013, Nucleic Acids Res..

[24]  S. Abedon,et al.  Phage treatment of human infections , 2011, Bacteriophage.

[25]  N. Perna,et al.  progressiveMauve: Multiple Genome Alignment with Gene Gain, Loss and Rearrangement , 2010, PloS one.

[26]  G. Volckaert,et al.  Quality-Controlled Small-Scale Production of a Well-Defined Bacteriophage Cocktail for Use in Human Clinical Trials , 2009, PloS one.

[27]  Andreas F Widmer,et al.  Infections associated with orthopedic implants , 2006, Current opinion in infectious diseases.

[28]  H. Ochs,et al.  Rituximab Inhibits the In Vivo Primary and Secondary Antibody Response to a Neoantigen, Bacteriophage phiX174 , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[29]  S. Abedon,et al.  Phage Therapy: Emergent Property Pharmacology , 2012 .

[30]  S. Abedon,et al.  Phage therapy in clinical practice: treatment of human infections. , 2010, Current pharmaceutical biotechnology.

[31]  S. Abedon,et al.  Phage therapy pharmacology. , 2010, Current pharmaceutical biotechnology.

[32]  M. Dabrowski,et al.  Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. , 1987, Archivum immunologiae et therapiae experimentalis.

[33]  J. Clavert,et al.  [Bacteriophage therapy of septic complications of orthopaedic surgery (author's transl]. , 1979, Revue de chirurgie orthopedique et reparatrice de l'appareil moteur.